Avelumab the new first line standard of care for advanced UC

Adding the checkpoint inhibitor avelumab to best supportive care (BSC) following induction chemotherapy for advanced urothelial carcinoma (UC) significantly improved overall survival (OS) compared with BSC alone, according to findings from the phase 3 JAVELIN Bladder 100 trial. The study, presented during the ASCO20 Virtual Scientific Program has been labelled ‘practice changing’ and according to ...